Prescribing information


▼Beovu® (brolucizumab) is indicated in adults for the treatment of neovascular (wet) AMD.1,2

Two randomised, multicentre, double-masked, active-controlled Phase lll studies.

HAWK and HARRIER: prospective head-to-head trials with q12w intervals immediately after loading in eligible patients*3

Diagram showing the treatment schedule for Beovu and aflibercept in the HAWK and HARRIER trials

  • Primary endpoint: Change in BCVA from baseline to Week 48, measured by ETDRS letter score4
  • Disease activity assessments (DAAs): Anatomical and functional parameters used to determine if patients were eligible for and remained on q12w interval4

Select baseline characteristics

  • Simple mean age: 76 years5
  • Simple mean VA: 61 letters read; comparable between treatment arms5
  • Baseline ocular characteristics for study eye were well balanced across treatment arms§5
  • 73% of patients with unilateral wet AMD4
  • 93% of patients were diagnosed ≤3 months prior to study entry4

Block of text with the words 'Beovu studied in 1,088 patients across centres worldwide3'


Image of the HAWK and HARRIER summary document


Download a handy one-page summary document on HAWK and HARRIER





VA is used to describe BCVA as identified in study protocol.
*Patients were eligible for a q12w interval if no disease activity was observed at Weeks 16 and 20.3
Beovu arms in HAWK: 3 mg (n=358), 6 mg (n=360); in HARRIER: 6 mg (n=370).3,4 HARRIER, confirmatory analysis in HAWK only (1-sided p values for superiority of Beovu).3 The 3 mg dosage is not licensed for use. The recommended dose is 6 mg brolucizumab (0.05 ml solution). Please refer to the SmPC for further information.
Comprehensive DAA criteria at Week 16: Decrease in VA of ≥5 letters compared with baseline; decrease in VA of ≥3 letters and CST increase ≥75 µm compared with Week 12; decrease in VA of ≥5 letters due to wet AMD disease activity compared with Week 12; new or worse IRF/IRC compared with Week 12. DAA criteria at Weeks 20, 32 and 44: Decrease in VA of ≥5 letters due to nAMD activity compared with Week 12.3,5
§Baseline characteristics include VA (letters read), CST-total, presence of fluid (IRF, SRF, sub-RPE), type of CNV and area associated with CNV lesion3,4

AMD, age-related macular degeneration; BCVA, best corrected visual acuity; CNV, choroidal neovascularisation; CST, central subfield thickness; DAA, disease activity assessment; ETDRS, Early Treatment Diabetic Retinopathy Study; IRC, intraretinal cysts; IRF, intraretinal fluid; nAMD, neovascular age-related macular degeneration; q8w, once every 8 weeks, q12w, once every 12 weeks; RPE, retinal pigment epithelium; SRF, subretinal fluid; VA, visual acuity.


  1. Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Great Britain, April 2022.
  2. Novartis Pharmaceuticals UK Ltd. Beovu® (brolucizumab) Summary of Product Characteristics, Northern Ireland, March 2022.
  3. Dugel PU, et al. Ophthalmology 2020;127:72–84.
  4. Novartis data on file. BRODOF20-002 Core Data Sheet; 2019.
  5. Dugel PU, et al. Ophthalmology 2020;127:72–84 (Supplementary information).
Rate this content: 
Average: 3 (8 votes)
UK | May 2022 | 209130

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at